ImmunityBio, Inc. logo

ImmunityBio, Inc.

NASDAQ:IBRX

Overview | Financials
Company Name ImmunityBio, Inc.
Symbol IBRX
Currency USD
Price 3.38
Market Cap 2,354,281,540
Dividend Yield 0%
52-week-range 1.25 - 10.53
Industry Biotechnology
Sector Healthcare
CEO Mr. Richard Gerald Adcock
Website https://immunitybio.com

An error occurred while fetching data.

About ImmunityBio, Inc.

ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The company also develops therapeutic agents, which are in

Related Stocks

Krystal Biotech, Inc. logo

Krystal Biotech, Inc.

KRYS

184.19 USD

Establishment Labs Holdings Inc. logo

Establishment Labs Holdings Inc.

ESTA

41.59 USD

Addus HomeCare Corporation logo

Addus HomeCare Corporation

ADUS

126.37 USD

Travere Therapeutics, Inc. logo

Travere Therapeutics, Inc.

TVTX

10.98 USD

Xenon Pharmaceuticals Inc. logo

Xenon Pharmaceuticals Inc.

XENE

38.47 USD

Ligand Pharmaceuticals Incorporated logo

Ligand Pharmaceuticals Incorporated

LGND

101.14 USD

Dynavax Technologies Corporation logo

Dynavax Technologies Corporation

DVAX

11.03 USD

ModivCare Inc. logo

ModivCare Inc.

MODV

32 USD

Supernus Pharmaceuticals, Inc. logo

Supernus Pharmaceuticals, Inc.

SUPN

33.84 USD

Financials

Numbers are in millions USD

Numbers are in millions USD